Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Why Jazz Pharmaceuticals (JAZZ) Is Drawing Investor Attention
Jazz Pharmaceuticals (JAZZ) is back on many watchlists after a strong recent run, with the stock up about 18% over the past month and roughly 39% in the past 3 months.
See our latest analysis for Jazz Pharmaceuticals.
At a share price of $239.83, Jazz Pharmaceuticals has seen momentum build, with a 30 day share price return of 18.5% contributing to a 1 year total shareholder return of 121.9%.
If you’re watching Jazz’s recent move and want to see what else is gaining attention in healthcare, consider using our screener to find 34 healthcare AI stocks.
With Jazz shares near $239 and an intrinsic value estimate implying a large discount, the question is whether the current price still underestimates the company’s pipeline and earnings power or if the market is already pricing in future growth.
Most Popular Narrative: 6.3% Overvalued
At $239.83, the most followed narrative for Jazz Pharmaceuticals pegs fair value at $225.53, so the current price sits modestly above that estimate based on a 7.4% discount rate.
The analysts have a consensus price target of $225.53 for Jazz Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $275.0, and the most bearish reporting a price target of just $188.0.
Want to see what sits underneath that fair value call? Revenue growth assumptions, margin rebuild and future earnings power all play a central role in this thesis.
Result: Fair Value of $225.53 (OVERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, patent expirations in the sleep franchise and execution risk around key oncology launches could still unsettle the earnings assumptions that underpin this fair value view.
Find out about the key risks to this Jazz Pharmaceuticals narrative.
Another Angle On Value
The analyst-based fair value narrative paints Jazz as about 6.3% overvalued at $239.83, yet Simply Wall St’s DCF output points to a future cash flow value of $847.26, implying the stock trades roughly 71.7% below that estimate. When two methods diverge this far, which set of assumptions would you lean on?
Look into how the SWS DCF model arrives at its fair value.
JAZZ Discounted Cash Flow as at May 2026
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Jazz Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.
Next Steps
With sentiment clearly mixed and both risks and rewards on the table, it makes sense to move quickly and weigh the full picture yourself using our 2 key rewards and 4 important warning signs
Looking for more investment ideas?
If you stop with Jazz, you could miss other opportunities that fit your style, so put the Simply Wall St screener to work for you.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include JAZZ.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com